Skip to main content
SpringerLink
Log in

3-0-demethyl fortimicin A: In vitro activity and interpretive zone standards for disk diffusion susceptibility tests

  • Originals
  • Published:
European Journal of Clinical Microbiology Aims and scope Submit manuscript

Abstract

The in vitro activity of 3-0-demethyl fortimicin A was compared to that of amikacin and tobramycin against 5,230 clinical isolates in four institutions. Amikacin and tobramycin were more active than 3-0-demethyl fortimicin A againstPseudomonas aeruginosa andAcinetobacter spp., but all three drugs had similar activity against theEnterobacteriaceae andStaphylococcus aureus. Additional tests with 335 representative gram-negative bacilli compared five different aminoglycosides, demonstrating differences with some isolates. Standardized disk diffusion tests were also performed with 30μg 3-0-demethyl fortimicin A disks, according to the National Committee for Clinical Laboratory Standards. The following interpretive breakpoints are proposed: ⩽ 11 mm for resistant (MIC ⩾32μg/ml) and ⩾ 15 mm for susceptible (MIC ⩽ 16μg/ml).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Martin, J. R., Johnson, P., Tadanier, J., Goldstein, A.: Synthesis of 3-0-demethyl fortimicin. Antimicrobial Agents and Chemotherapy 1980, 18: 761–765.

    PubMed  Google Scholar 

  2. Jones, R. N., Barry, A. L., Fuchs, P. C., Gavan, T. L., Sommers, H. M., Gerlach, E. H.: Fortimicin A: A collaborative in vitro susceptibility comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 1979, 16: 823–826.

    PubMed  Google Scholar 

  3. Jones, R. N., Thornsberry, C., Barry, A. L., Packer, R. R., Baker, C. N., Badal, R. E.: Compound A49759, the 3-0-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibiotics. Antimicrobial Agents and Chemotherapy 1980, 18: 773–779.

    PubMed  Google Scholar 

  4. Neu, H. C.: The in vitro activity of 0-demethylfortimicin. Journal of Antimicrobial Chemotherapy 1983, 11: 181–185.

    PubMed  Google Scholar 

  5. Girolami, R. L., Stamm, J. M.: Comparative antimicrobial activity of 0-demethyl fortimicin A, a derivative of fortimicin A. Antimicrobial Agents and Chemotherapy 1980, 18: 766–772.

    PubMed  Google Scholar 

  6. Bauer, A. W., Kirby, W. M. M., Sherris, J. C., Turck, M.: Antibiotic susceptibility testing by a standardized disk method. American Journal of Clinical Pathology 1966, 45: 493–496.

    PubMed  Google Scholar 

  7. NCCLS Tentative Standard, M2-T3: Performance Standards for Antimicrobial Disk Susceptibility Tests. National Committee for Clinical Laboratory Standards, Villanova, PA, 1983, p. 1–38.

  8. NCCLS Tentative Standard, M7-T: Standard Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. National Committee for Clinical Laboratory Standards, Villanova, PA, 1983, p. 1–31.

  9. Miller, G. H., Sabatelli, F. J., Hare, R. S., Waitz, J. A.: Survey of aminoglycoside resistance patterns. Developments in Industrial Microbiology 1980, 21: 91–104.

    Google Scholar 

  10. Barry, A. L., Thornsberry, C., Jones, R. N.: Proposed zone standards for interpretation of fortimicin A disk diffusion tests. Journal of Clinical Microbiology 1983, 18: 440–442.

    PubMed  Google Scholar 

  11. Barry, A. L., Thornsberry, C., Jones, R. N.: Gentamicin and amikacin disk susceptibility tests withPseudomonas aeruginosa; definition of minimal inhibitory concentration correlates for susceptible and resistant categories. Journal of Clinical Microbiology 1981, 13: 1000–1003.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Clinical Microbiology Institute, 97062, Tualatin, Oregon, USA

    A. L. Barry

  2. Kaiser-Permanente Regional Laboratory, 97015, Clackamas, Oregon, USA

    R. N. Jones

  3. Centers for Disease Control, 30333, Atlanta, Georgia, USA

    C. Thornsberry

  4. The Cleveland Clinic Foundation, 44106, Cleveland, Ohio, USA

    T. L. Gavan

  5. St. Francis Hospital, 67214, Wichita, Kansas, USA

    E. H. Gerlach

  6. Northwestern Memorial Hospital, 60611, Chicago, Illinois, USA

    H. M. Sommer

Authors
  1. A. L. Barry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. N. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Thornsberry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. L. Gavan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. H. Gerlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. M. Sommer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barry, A.L., Jones, R.N., Thornsberry, C. et al. 3-0-demethyl fortimicin A: In vitro activity and interpretive zone standards for disk diffusion susceptibility tests. Eur. J, Clin. Microbiol. 3, 531–537 (1984). https://doi.org/10.1007/BF02013613

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02013613

Keywords

Search

Navigation